Professor Jose Russo is the Director of the Irma H. Russo, MD-Breast Cancer Research Laboratory. He is a Molecular and Experimental Pathologist and board-certified in Surgical Pathology by the American College of Pathologists. He has special interest in breast cancer aiming to elucidate the mechanism of hormonal and chemical carcinogenesis, and to develop new preventive strategies against sporadic and non-sporadic breast cancer. He has pioneered the role of estrogen as a carcinogen in the human breast and developed the concept that pregnancy related hormones induce differentiation of the breast mimicking pregnancy as a new paradigm in the prevention of breast cancer. Professor Russo is author of more than 420 peer reviewed publications, 450 research abstracts and 15 books. He has received numerous research grant awards among them from the National Cancer Institute of the US National Institutor of Health, the USA Department of Defense, the American Cancer Society, The Komen foundation for the Cure and the Avon Foundation. He has trained 55 MDs and PhDs in breast cancer research and established numerous collaborations with scientists around the world.Dr. Yanrong Su, MD, PhD is Assistant Research Professor and joined Dr Russo’s team of researchers in April of 2011. She received her doctoral degree from Peking University in China in 2003. For the last eight years, Dr. Su has been working in breast cancer research field, concentrated her attention on epigenetic modifications induced by pregnancy and human chorionic gonadotropin in human and rat mammary glands, and use of epigenetic compounds for breast cancer treatment.Dr. Magda Johanna Vandeloo joined Dr Russo’s team in November of 2018 as a Visiting Research Scientist. Dr. Vandeloo is a Doctoral Researcher in ‘Biomedical Sciences’ at the University of Leuven ‘Faculty of Medicine’ and the Hasselt University ‘Medicine & Life Sciences’ in Belgium. The subject of her research interest is: Reproductive Factors, Air Pollution and Mammographic Breast Density.

• 1. Defining breast cancer.- 2: Breast Cancer Recurrence and Survival.- 3: Synopsis of the Treatment of Breast Cancer.- 4: The Present Treatment of Hereditary Breast Cancer.- 5: Basis for the Epigenetic Treatment of Triple Negative Breast Cancer.- 6: A New Treatment Strategy foe BRCA1 Related Breast Cancer.- 7: Present Options in the Prevention of Breast Cancer.- 8: The Physiological Basis of Breast Cancer Prevention.- 9: The Present and Future of Screening in Breast Cancer Prevention.- 10: A Vision of the Future.

Professor Jose Russo is the Director of the Irma H. Russo, MD-Breast Cancer Research Laboratory. He is a Molecular and Experimental Pathologist and board-certified in Surgical Pathology by the American College of Pathologists. He has special interest in breast cancer aiming to elucidate the mechanism of hormonal and chemical carcinogenesis, and to develop new preventive strategies against sporadic and non-sporadic breast cancer. He has pioneered the role of estrogen as a carcinogen in the human breast and developed the concept that pregnancy related hormones induce differentiation of the breast mimicking pregnancy as a new paradigm in the prevention of breast cancer. Professor Russo is author of more than 420 peer reviewed publications, 450 research abstracts and 15 books. He has received numerous research grant awards among them from the National Cancer Institute of the US National Institutor of Health, the USA Department of Defense, the American Cancer Society, The Komen foundation for the Cure and the Avon Foundation. He has trained 55 MDs and PhDs in breast cancer research and established numerous collaborations with scientists around the world.Dr. Yanrong Su, MD, PhD is Assistant Research Professor and joined Dr Russo’s team of researchers in April of 2011. She received her doctoral degree from Peking University in China in 2003. For the last eight years, Dr. Su has been working in breast cancer research field, concentrated her attention on epigenetic modifications induced by pregnancy and human chorionic gonadotropin in human and rat mammary glands, and use of epigenetic compounds for breast cancer treatment.Dr. Magda Johanna Vandeloo joined Dr Russo’s team in November of 2018 as a Visiting Research Scientist. Dr. Vandeloo is a Doctoral Researcher in ‘Biomedical Sciences’ at the University of Leuven ‘Faculty of Medicine’ and the Hasselt University ‘Medicine & Life Sciences’ in Belgium. The subject of her research interest is: Reproductive Factors, Air Pollution and Mammographic Breast Density.

• 1. Defining breast cancer.- 2: Breast Cancer Recurrence and Survival.- 3: Synopsis of the Treatment of Breast Cancer.- 4: The Present Treatment of Hereditary Breast Cancer.- 5: Basis for the Epigenetic Treatment of Triple Negative Breast Cancer.- 6: A New Treatment Strategy foe BRCA1 Related Breast Cancer.- 7: Present Options in the Prevention of Breast Cancer.- 8: The Physiological Basis of Breast Cancer Prevention.- 9: The Present and Future of Screening in Breast Cancer Prevention.- 10: A Vision of the Future.

Professor Jose Russo is the Director of the Irma H. Russo, MD-Breast Cancer Research Laboratory. He is a Molecular and Experimental Pathologist and board-certified in Surgical Pathology by the American College of Pathologists. He has special interest in breast cancer aiming to elucidate the mechanism of hormonal and chemical carcinogenesis, and to develop new preventive strategies against sporadic and non-sporadic breast cancer. He has pioneered the role of estrogen as a carcinogen in the human breast and developed the concept that pregnancy related hormones induce differentiation of the breast mimicking pregnancy as a new paradigm in the prevention of breast cancer. Professor Russo is author of more than 420 peer reviewed publications, 450 research abstracts and 15 books. He has received numerous research grant awards among them from the National Cancer Institute of the US National Institutor of Health, the USA Department of Defense, the American Cancer Society, The Komen foundation for the Cure and the Avon Foundation. He has trained 55 MDs and PhDs in breast cancer research and established numerous collaborations with scientists around the world.Dr. Yanrong Su, MD, PhD is Assistant Research Professor and joined Dr Russo’s team of researchers in April of 2011. She received her doctoral degree from Peking University in China in 2003. For the last eight years, Dr. Su has been working in breast cancer research field, concentrated her attention on epigenetic modifications induced by pregnancy and human chorionic gonadotropin in human and rat mammary glands, and use of epigenetic compounds for breast cancer treatment.Dr. Magda Johanna Vandeloo joined Dr Russo’s team in November of 2018 as a Visiting Research Scientist. Dr. Vandeloo is a Doctoral Researcher in ‘Biomedical Sciences’ at the University of Leuven ‘Faculty of Medicine’ and the Hasselt University ‘Medicine & Life Sciences’ in Belgium. The subject of her research interest is: Reproductive Factors, Air Pollution and Mammographic Breast Density.

• 1. Defining breast cancer.- 2: Breast Cancer Recurrence and Survival.- 3: Synopsis of the Treatment of Breast Cancer.- 4: The Present Treatment of Hereditary Breast Cancer.- 5: Basis for the Epigenetic Treatment of Triple Negative Breast Cancer.- 6: A New Treatment Strategy foe BRCA1 Related Breast Cancer.- 7: Present Options in the Prevention of Breast Cancer.- 8: The Physiological Basis of Breast Cancer Prevention.- 9: The Present and Future of Screening in Breast Cancer Prevention.- 10: A Vision of the Future.